Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Sarepta Therapeutics (SRPT – Research Report). The ...

Analyst Gil Blum from Needham maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) and keeping the price target at ...

Also Read: Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy Dyne ... Analysis of muscle biopsy data for the 6.8 mg/kg Q8W cohort ...

Duchenne muscular dystrophy occurs when that gene fails ... These may include: Muscle biopsy. A small piece of muscle tissue is removed and examined to confirm the diagnosis or rule out another ...

Additionally, Dyne Therapeutics is progressing with its DYNE-251 program for Duchenne muscular dystrophy (DMD), aiming ... be due to factors such as poor biopsy sampling, missing baseline data ...

The diagnosis of DMD was based on standard criteria: progressive symmetrical muscle weakness and other signs and symptoms starting before the age of 5 years; elevated serum creatinine kinase activity; ...

Investing.com -- Shares of Dyne Therapeutics, Inc. (Nasdaq: DYN) plummeted 25% as the biotechnology firm reported early trial data for its experimental therapy for myotonic dystrophy type 1 (DM1), a ...

Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...

Liquid biopsy is one of them. A traditional biopsy usually involves taking a tiny tissue sample from the body to diagnose a disease and to understand the extent of its progression. But liquid ...

While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...